# EDGAR Filing Document

**Accession Number:** 0001508910
**File Stem:** 0000929638-26-000874
**Filing Date:** 2026-3
**Character Count:** 8319
**Document Hash:** d907187be47e8817a3b84f0d93b329bd
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000929638-26-000874.hdr.sgml**: 20260305

**ACCESSION NUMBER**: 0000929638-26-000874

**CONFORMED SUBMISSION TYPE**: SCHEDULE 13D/A

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20260305

**DATE AS OF CHANGE**: 20260305

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Ventyx Biosciences, Inc.
- **CENTRAL INDEX KEY:** 0001851194
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 832996852
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D/A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-92974
- **FILM NUMBER:** 26724398

**BUSINESS ADDRESS:**
- **STREET 1:** 12790 EL CAMINO REAL, SUITE 200
- **CITY:** SAN DIEGO
- **STATE:** CA
- **ZIP:** 92130
- **BUSINESS PHONE:** 7604076511

**MAIL ADDRESS:**
- **STREET 1:** 12790 EL CAMINO REAL, SUITE 200
- **CITY:** SAN DIEGO
- **STATE:** CA
- **ZIP:** 92130
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Subramaniam Somu
- **CENTRAL INDEX KEY:** 0001508910

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D/A

**MAIL ADDRESS:**
- **STREET 1:** C/O VENTYX BIOSCIENCES, INC.
- **STREET 2:** 12790 EL CAMINO REAL, SUITE 200
- **CITY:** SAN DIEGO
- **STATE:** CA
- **ZIP:** 92130

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## SCHEDULE 13D

### Under the Securities Exchange Act of 1934

**(Amendment No. 15)**

**Ventyx Biosciences, Inc.**

*(Name of Issuer)*

**Common stock, par value $0.0001 per share**

*(Title of Class of Securities)*

**92332V107**

*(CUSIP Number)*

**Somasundaram Subramaniam**<br>New Science Ventures<br>500 West Putnam Avenue, Suite 400<br>Greenwich CT 06830<br>(212) 688-5100

*(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)*

**03/04/2026**

*(Date of Event Which Requires Filing of this Statement)*

| **CUSIP No.** | **92332V107** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Subramaniam Somu** | Name of reporting person<br>**Subramaniam Somu** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**AF** | Source of funds (See Instructions)<br>**AF** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**X1** | Citizenship or place of organization<br>**X1** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**0.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**0.00** | Aggregate amount beneficially owned by each reporting person<br>**0.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**0%** | Percent of class represented by amount in Row (11)<br>**0%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**IN** | Type of Reporting Person (See Instructions)<br>**IN** | |

---

**Item 1. Security and Issuer**

**(a) Title of Class of Securities:**
Common stock, par value $0.0001 per share

**(b) Name of Issuer:**
Ventyx Biosciences, Inc.

**(c) Address of Issuer's Principal Executive Offices:**
12790 El Camino Real, Suite 200, San Diego, CA, 92130

This Amendment No. 15 ("Amendment No. 15") amends the Statement of Beneficial Ownership on Schedule 13D jointly filed with the Securities and Exchange Commission (the "Commission") by NSV Investments I, L.P., a Delaware limited partnership, NSV Partners II, LLC, a Delaware limited liability company, NSV Partners III, L.P., a Delaware limited partnership, NSV Partners III GP, LLC, a Delaware limited liability company and Somasundaram Subramaniam, a United States citizen (the "Reporting Person"), on October 29, 2021, and amended on September 21, 2022, December 16, 2022, December 30, 2022, March 2, 2023, March 22, 2023, April 6, 2023, July 11, 2023, July 19, 2023, March 8, 2024, March 13, 2024, June 26, 2024, March 12, 2025, April 1, 2025 and January 9, 2026 (as amended, the "Schedule 13D"), with respect to the shares of common stock, par value $0.0001 per share ("Common Stock"), of Ventyx Biosciences, Inc. (the "Issuer"). Except as specifically provided herein, this Amendment No. 15 does not modify any of the information previously reported in the Schedule 13D, which remains unchanged.

**Item 4. Purpose of Transaction**

Item 4 of the Schedule 13D is hereby amended and supplemented as follows:

On February 27, 2026, 474,632 shares held by NSV Partners III, L.P. and 220,086 shares held by New Science Ventures, LLC, respectively, were distributed on a pro rata basis for no consideration. The Reporting Person is the majority member and managing member of (i) NSV Partners III GP, LLC, which is the general partner of NSV Partners III, L.P., and (ii) New Science Ventures, LLC.

On March 4, 2026, pursuant to the Agreement and Plan of Merger, dated as of January 7, 2026 (the "Merger Agreement"), by and among the Issuer, Eli Lilly and Company, an Indiana corporation ("Parent"), and RYLS Merger Corporation, a Delaware corporation and wholly-owned subsidiary of Parent ("Merger Sub"), Merger Sub merged with and into the Issuer, with the Issuer surviving the Merger as a wholly owned subsidiary of Parent (the "Merger"). At the effective time of the Merger (the "Effective Time"), all of the shares of the Common Stock beneficially owned by the Reporting Person immediately prior to the Effective Time were converted into the right to receive $14.00 per share in cash, less any applicable tax withholding (the "Common Merger Consideration"), and all of the shares of Common Stock acquirable upon the exercise of stock options held by the Reporting Person immediately prior to the Effective Time were canceled and converted into the right to receive an amount in cash, without interest and less any applicable tax withholdings, equal to the product of (x) the total number of shares of Common Stock subject to such stock option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Common Merger Consideration over the applicable exercise price per share of Common Stock under such stock option. 

As a result of the Merger, as of the Effective Time, the Reporting Person no longer beneficially owned any securities of the Issuer, and the Voting and Support Agreement described in Item 4 of Amendment No. 14 to this Schedule 13D terminated in accordance with its terms.

**Item 5. Interest in Securities of the Issuer**

**(a)**
Item 5(a) of the Schedule 13D is hereby amended and restated as follows:

(a) See Item 4 of Amendment No. 15, which is incorporated by reference herein.

**(b)**
Item 5(b) of the Schedule 13D is hereby amended and restated as follows:

(b) See Item 4 of Amendment No. 15, which is incorporated by reference herein.

**(c)**
(c) See Item 4 of Amendment No. 15, which is incorporated by reference herein.

**Item 6. Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer.**

n/a

### SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Subramaniam Somu

**Signature:** /s/ Somasundaram Subramaniam*

**Name/Title:** Somasundaram Subramaniam

**Date:** 03/05/2026